Jones, Brad

Publications

Sort by

Co-Author Network

selected publications

Persistence of a Skewed Repertoire of NK Cells in People with HIV-1 on Long-Term Antiretroviral Therapy. Journal of immunology (Baltimore, Md. : 1950). 2024 Academic Article GET IT
Circulating CD4+ T cells in people with HIV and history of pulmonary tuberculosis have more intact HIV DNA. 2024 GET IT
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. iScience. 2023 Academic Article GET IT
Whack-a-virus: HIV-specific T cells play an exhausting game. Cell host & microbe. 2023 Academic Article GET IT
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nature medicine. 2023 Academic Article GET IT
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1. Frontiers in immunology. 2023 Academic Article GET IT
Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. Cell. 2023 Academic Article GET IT
Times cited: 2
The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells. JCI insight. 2023 Academic Article GET IT
Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV. International journal of nanomedicine. 2023 Academic Article GET IT
Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV. 2023 GET IT
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. AIDS research and human retroviruses. 2023 Academic Article GET IT
CD8⁺ T cells promote HIV latency by remodeling CD4⁺ T cell metabolism to enhance their survival, quiescence, and stemness. Immunity. 2023 Academic Article GET IT
Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA. Journal of virus eradication. 2023 Academic Article GET IT
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8⁺ T cell immunity. Nature communications. 2022 Academic Article GET IT
Times cited: 18
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nature medicine. 2022 Academic Article GET IT
Times cited: 34
Inhibition of major histocompatibility complex-I antigen presentation by sarbecovirus ORF7a proteins. Proceedings of the National Academy of Sciences of the United States of America. 2022 Academic Article GET IT
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8⁺ T-cells. Nature communications. 2022 Academic Article GET IT
Times cited: 14
Potential multi-modal effects of provirus integration on HIV-1 persistence: lessons from other viruses. Trends in immunology. 2022 Review GET IT
No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART. AIDS (London, England). 2022 Academic Article GET IT
Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. Frontiers in cellular and infection microbiology. 2022 Academic Article GET IT
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. The Lancet. Microbe. 2022 Academic Article GET IT
Times cited: 2
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature medicine. 2021 Review GET IT
Times cited: 27
T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice. The Journal of clinical investigation. 2021 Academic Article GET IT
Characterizing the Relationship Between Neutralization Sensitivity and env Gene Diversity During ART Suppression. Frontiers in immunology. 2021 Academic Article GET IT
Selective BCL-X_L Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Ex Vivo Reservoirs. Journal of virology. 2021 Academic Article GET IT
A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. The Journal of experimental medicine. 2021 Academic Article GET IT
HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI insight. 2021 Academic Article GET IT
Times cited: 36
The Intact Non-Inducible Latent HIV-1 Reservoir is Established In an In Vitro Primary T_CM Cell Model of Latency. Journal of virology. 2021 Academic Article GET IT
Times cited: 9
HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nature communications. 2021 Academic Article GET IT
Times cited: 51
Editorial: On two fronts: synergies and costs at the interface of responses to two global viral pandemics. Current opinion in HIV and AIDS. 2021 Editorial Article GET IT
Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV. Journal of virology. 2020 Article GET IT
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020 Academic Article GET IT
Times cited: 93
Human splice factors contribute to latent HIV infection in primary cell models and blood CD4+ T cells from ART-treated individuals. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 17
Immunological approaches to HIV cure. Seminars in immunology. 2020 Information Resource GET IT
Times cited: 6
Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV. Molecular therapy. Methods & clinical development. 2020 Academic Article GET IT
Times cited: 9
Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. The Journal of infectious diseases. 2020 Academic Article GET IT
Times cited: 67
Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents. Antimicrobial agents and chemotherapy. 2020 Academic Article GET IT
Times cited: 3
CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir. Journal of immunology (Baltimore, Md. : 1950). 2020 Academic Article GET IT
Times cited: 3
BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 66
Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 28
Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8⁺ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal. Journal of virology. 2020 Academic Article GET IT
Times cited: 17
Differences in inducibility of the latent HIV reservoir in perinatal and adult infection. JCI insight. 2020 Academic Article GET IT
Times cited: 21
PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function. Nano research. 2020 Academic Article GET IT
Times cited: 16
Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts. mBio. 2020 Academic Article GET IT
Times cited: 26
T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS (London, England). 2020 Academic Article GET IT
Times cited: 22
HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform. Molecular therapy. Methods & clinical development. 2019 Academic Article GET IT
Times cited: 15
Transcriptomic analysis of human endogenous retroviruses in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America. 2019 Letter GET IT
Times cited: 8
Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression. PLoS computational biology. 2019 Academic Article GET IT
Times cited: 68
HTLV-1 as a Model for Virus and Host Coordinated Immunoediting. Frontiers in immunology. 2019 Academic Article GET IT
Times cited: 8
Have Cells Harboring the HIV Reservoir Been Immunoedited?. Frontiers in immunology. 2019 Academic Article GET IT
Times cited: 14
Modeling HIV-1 Latency Using Primary CD4⁺ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of virology. 2019 Academic Article GET IT
Times cited: 10
HIV Controllers Exhibit Effective CD8⁺ T Cell Recognition of HIV-1-Infected Non-activated CD4⁺ T Cells. Cell reports. 2019 Academic Article GET IT
Times cited: 18
Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs. Journal of virology. 2019 Academic Article GET IT
Times cited: 20
Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nature communications. 2019 Academic Article GET IT
Times cited: 129
Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. Journal of virology. 2018 Academic Article GET IT
Times cited: 20
Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy. AIDS research and human retroviruses. 2018 Academic Article GET IT
Times cited: 4
Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI insight. 2018 Academic Article GET IT
Times cited: 64
Evidence that CD32a does not mark the HIV-1 latent reservoir. Nature. 2018 Academic Article GET IT
Times cited: 39
HLA-C downregulation by HIV-1 adapts to host HLA genotype. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 21
Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS research and human retroviruses. 2018 Academic Article GET IT
Times cited: 20
Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Frontiers in immunology. 2018 Information Resource GET IT
Times cited: 26
HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 15
The human IL-15 superagonist ALT-803 directs SIV-specific CD8⁺ T cells into B-cell follicles. Blood advances. 2018 Academic Article GET IT
Times cited: 64
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 141
T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS pathogens. 2017 Academic Article GET IT
Times cited: 36
Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell host & microbe. 2017 Academic Article GET IT
Times cited: 245
IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI insight. 2017 Academic Article GET IT
Times cited: 9
Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials. 2016 Academic Article GET IT
Times cited: 55
Antiviral CD8⁺ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion. Immunity. 2016 Academic Article GET IT
Times cited: 54
T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy. 2016 Information Resource GET IT
Times cited: 32
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 124
HIV-specific CD8⁺ T cells and HIV eradication. The Journal of clinical investigation. 2016 Information Resource GET IT
Times cited: 104
A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion. Journal of immunological methods. 2015 Academic Article GET IT
Times cited: 15
Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis. Journal of translational medicine. 2014 Academic Article GET IT
Times cited: 15
Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS pathogens. 2014 Academic Article GET IT
Times cited: 165
Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication. PloS one. 2014 Academic Article GET IT
Times cited: 8
LINE-1 retrotransposable element DNA accumulates in HIV-1-infected cells. Journal of virology. 2013 Academic Article GET IT
Times cited: 47
Human endogenous retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods. Journal of negative results in biomedicine. 2013 Academic Article GET IT
Times cited: 12
High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood. 2012 Academic Article GET IT
Times cited: 55
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. The Journal of clinical investigation. 2012 Academic Article GET IT
Times cited: 67
Short communication: HIV type 1 accumulates in influenza-specific T cells in subjects receiving seasonal vaccination in the context of effective antiretroviral therapy. AIDS research and human retroviruses. 2012 Academic Article GET IT
Times cited: 11
Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection. PloS one. 2012 Academic Article GET IT
Times cited: 18
Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PloS one. 2012 Academic Article GET IT
Times cited: 71
Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 42
Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Frontiers in immunology. 2012 Academic Article GET IT
Times cited: 101
Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 51
Mucosal correlates of isolated HIV semen shedding during effective antiretroviral therapy. Mucosal immunology. 2012 Academic Article GET IT
Times cited: 24
Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening. Clinical and vaccine immunology : CVI. 2011 Academic Article GET IT
Times cited: 11
Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. The Journal of experimental medicine. 2011 Academic Article GET IT
Times cited: 57
Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. Journal of virology. 2011 Academic Article GET IT
Times cited: 50
HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications. PLoS neglected tropical diseases. 2011 Academic Article GET IT
Times cited: 21
HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. European journal of immunology. 2010 Academic Article GET IT
Times cited: 74
A synthetic globotriaosylceramide analogue inhibits HIV-1 infection in vitro by two mechanisms. Glycoconjugate journal. 2010 Academic Article GET IT
Times cited: 24
The impact of CCL3L1 copy number in an HIV-1-infected white population. AIDS (London, England). 2010 Academic Article GET IT
Times cited: 4
HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. Journal of immunology (Baltimore, Md. : 1950). 2010 Academic Article GET IT
Times cited: 83
Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PloS one. 2010 Academic Article GET IT
Times cited: 14
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (London, England). 2009 Academic Article GET IT
Times cited: 105
Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations. Journal of virology. 2009 Academic Article GET IT
Times cited: 18
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. The Journal of experimental medicine. 2008 Academic Article GET IT
Times cited: 607
HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PloS one. 2008 Academic Article GET IT
Times cited: 27
CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine. 2008 Academic Article GET IT
Times cited: 46
Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition. PloS one. 2008 Academic Article GET IT
Times cited: 72
T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS pathogens. 2007 Academic Article GET IT
Times cited: 102
Advances in celiac disease. Current opinion in gastroenterology. 2006 Information Resource GET IT
Times cited: 16

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Defining and then Maximizing the Footprint of CTL Selection on HIV Integration Site Landscapes to Optimize Cure Strategies awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2024 - 2028
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2023 - 2028
Mechanisms of CTL Resistance in HIV Reservoirs awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2022 - 2026
REACH: Research Enterprise to Advance a Cure for HIV awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2021 - 2026
A participant-derived xenograft mouse model to study T-cell-mediated viral control and mRNA vaccine strategies awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2022 - 2024
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirs awarded by National Institute of Allergy & Infectious Diseases Principal Investigator 2019 - 2024

Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence awarded by National Institute of Mental Health Co-Investigator 2023 - 2027

Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV awarded by National Heart, Lung, & Blood Institute Key Personnel 2023 - 2027

Understanding Immune Evasion by HIV-1 Repliclones awarded by National Institute of Diabetes & Digestive & Kidney Diseases Principal Investigator Subaward 2021 - 2026
Enterprise for Research and Advocacy to Stop and Eradicate HIV (ERASE-HIV) awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2021 - 2026
Deciphering Mechanisms of HIV Latency Reversal in Perinatal Infection awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2020 - 2025
Measurement of HIV Proviral Reservoir Using Intact Proviral DNA Assay awarded by Blood & Marrow Transplant Clinical Trials Network Principal Investigator Subaward 2020 - 2025
Immunologic control of HIV-1 through combination bNAbs and biologics awarded by National Institute of Allergy & Infectious Diseases Principal Investigator Subaward 2019 - 2024

more ...

less ...

Background

education and training

Ph.D., University of Toronto (Canada) 2011
B.Sc., Simon Fraser University (Canada) 2004

Contact

full name

Brad Jones

primary email

rbjones@med.cornell.edu

VIVO Weill Cornell Medical College

Brad Jones Associate Professor of Immunology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email